Arun Kumar Arumugam Raajasekar
Hematology & Oncology · Yuma, AZNPI 1801143722
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $942 of the $1,140 with a category attached, or 82.6%. Tersera Therapeutics LLC accounts for 82.6% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $942, more than ten times the $21 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in AZ, where the typical reported total is $6,870.
Across 7 payments — averaging $162.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tersera Therapeutics LLC$942
- AstraZeneca$71
- Johnson & Johnson$62
- Karyopharm Therapeutics Inc.$24
- Sanofi$21
- Gilead$20
Across 18 payments — averaging $20,281 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$140K
- Novartis$117K
- AstraZeneca$77K
- Janssen Research & Development, LLC$31K
What the payments were for
- Consulting fees$94283%
- Food & beverage$837%
- Education$11510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tersera Therapeutics LLC | 2 | $942 |
| AstraZeneca | 1 | $71 |
| Johnson & Johnson | 1 | $62 |
| Karyopharm Therapeutics Inc. | 1 | $24 |
| Sanofi | 1 | $21 |
| Gilead | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MARGENZA$942
How this compares
$1,140 in reported general payments places this provider in the 25th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 130 | $1,768,259 |
| CabometyxCabozantinib S-Malate | 46 | $1,101,174 |
| PomalystPomalidomide | 15 | $357,020 |
| Abiraterone Acetate | 147 | $269,289 |
| NubeqaDarolutamide | 17 | $230,872 |
| InlytaAxitinib | 11 | $213,626 |
| EliquisApixaban | 26 | $15,797 |
| Enoxaparin Sodium | 11 | $2,457 |
| Prochlorperazine Maleate | 133 | $1,793 |
| Ondansetron Hcl | 119 | $1,735 |
| Prednisone | 155 | $1,116 |
| Dexamethasone | 61 | $1,102 |
| Potassium Chloride | 21 | $946 |
| Hydroxyurea | 28 | $772 |
| Triamcinolone Acetonide | 14 | $647 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Yuma
- Michael LysterYuma$84K
- Sujith KalmadiChandler$1.4M
- Jeffrey SchriberScottsdale$715K
- Javier MunozPhoenix$638K
- Tanios Bekaii-SaabScottsdale$527K
- Rajesh KukunoorScottsdale$499K
- Sumit MadanGilbert$422K
- Christopher ChenTucson$370K
- Rachna ShroffTucson$250K
- Govardhanan NagaiahGoodyear$222K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.